1. Home
  2. SST vs NVNO Comparison

SST vs NVNO Comparison

Compare SST & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$4.31

Market Cap

67.7M

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$0.36

Market Cap

16.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
NVNO
Founded
2013
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.7M
16.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SST
NVNO
Price
$4.31
$0.36
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
28.3K
429.2K
Earning Date
11-05-2025
10-31-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,784,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$0.30
52 Week High
$15.00
$5.62

Technical Indicators

Market Signals
Indicator
SST
NVNO
Relative Strength Index (RSI) 51.26 45.06
Support Level $3.91 $0.31
Resistance Level $4.63 $0.37
Average True Range (ATR) 0.34 0.03
MACD 0.02 0.01
Stochastic Oscillator 59.30 69.79

Price Performance

Historical Comparison
SST
NVNO

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: